Acute On Chronic Liver Failure (ACLF) Pipeline Insight

DelveInsight’s, “Acute On Chronic Liver Failure (ACLF) - Pipeline Insight, 2025” report provides comprehensive insights about 3+ companies and 5+ pipeline drugs in Acute On Chronic Liver Failure (ACLF) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Geography Covered

• Global coverage

 

Acute On Chronic Liver Failure (ACLF): Understanding

Acute On Chronic Liver Failure (ACLF): Overview

Acute on chronic liver failure (ACLF) is a life-threatening clinical syndrome characterized by the sudden and rapid deterioration of liver function in individuals with pre-existing chronic liver disease or cirrhosis. This abrupt decline often results in multi-organ failure and carries a high risk of short-term mortality. Several international bodies including APASL, EASL-CLIF, and NACSELD have proposed varying definitions and diagnostic criteria for ACLF, differing mainly in their classification of liver disease severity and the evaluation of organ failures. The underlying pathophysiology involves widespread hepatic necrosis, intense systemic inflammation, and immune dysregulation, often described as a cytokine storm. This immune over activation is typically followed by immune paralysis, leaving patients highly susceptible to infections and sepsis. Common precipitating factors include infections, acute alcoholic hepatitis, viral reactivation, and drug-induced liver injury, although in many cases, no clear trigger is identified. Alcohol use and chronic hepatitis B or C infections are among the most frequent underlying conditions. ACLF tends to follow a dynamic and potentially reversible course, with prognosis worsening significantly as the number of failing organs increases. Prognostic scoring systems such as CLIF-C ACLF and MELD are used to guide clinical decisions, including the consideration of liver transplantation. Management primarily involves supportive care for organ dysfunction, control of infections, and addressing the precipitating events. Liver transplantation remains the only curative option, although eligibility is often constrained by the severity of illness and comorbidities.

The diagnosis of acute on chronic liver failure (ACLF) relies on specific criteria established by international organizations, with regional differences in emphasis and thresholds. The APASL definition focuses on acute hepatic insult in patients with chronic liver disease (excluding prior decompensation), marked by jaundice (bilirubin ≥ 5 mg/dL) and coagulopathy (INR ≥ 1.5), followed by ascites or encephalopathy within four weeks. In contrast, the EASL-CLIF criteria apply to patients with cirrhosis and acute decompensation, using the CLIF-SOFA score to classify ACLF grades based on the number and type of organ failures. The Chinese (CMA) criteria include rapidly worsening jaundice (TBIL ≥ 10 mg/dL), coagulopathy, and decompensated ascites, with or without encephalopathy, and categorize disease severity into stages. Despite differences, all systems require evidence of acute decompensation on a background of chronic liver disease. Key diagnostic markers include elevated bilirubin, INR, hepatic encephalopathy, ascites, and organ dysfunction. Precipitating events such as infections, alcohol use, viral flares, or drugs must be identified or excluded. Tools like the CLIF-SOFA score, MELD-Na, and total bilirubin help stratify risk and guide management decisions.

The treatment of acute on chronic liver failure (ACLF) centers on intensive supportive care, early management of precipitating factors, and timely evaluation for liver transplantation. ICU-level monitoring is often required, with organ support such as dialysis, vasopressors, and ventilation provided as needed. Prompt identification and treatment of infections are crucial, as they are both common triggers and complications. Liver transplantation is the only proven curative option, with early referral improving survival outcomes. Emerging therapies like plasma exchange, artificial liver support systems, and microbiome modulation show potential but remain investigational.

For a comprehensive understanding of market dynamics, competitive landscape, and future outlook, explore the full ACLF Market Report

"Acute On Chronic Liver Failure (ACLF)- Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute On Chronic Liver Failure (ACLF) pipeline landscape is provided which includes the disease overview and Acute On Chronic Liver Failure (ACLF) treatment guidelines. The assessment part of the report embraces, in depth Acute On Chronic Liver Failure (ACLF) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute On Chronic Liver Failure (ACLF) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Acute On Chronic Liver Failure (ACLF) R&D. The therapies under development are focused on novel approaches to treat/improve Acute On Chronic Liver Failure (ACLF).

 

Acute On Chronic Liver Failure (ACLF) Emerging Drugs Chapters

This segment of the Acute On Chronic Liver Failure (ACLF) report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Acute On Chronic Liver Failure (ACLF) Emerging Drugs

• F573: Gyre Therapeutics

F573 is a caspase inhibitor and potential Category 1 new drug for the treatment of acute/acute on-chronic liver failure (“ALF/ACLF”). The main mechanism of F573 is to inhibit the activity of the caspase family, including caspases 1, 3, 6, 7, 8 and 9 and to reduce the cleavage effects on poly-ADP-ribose polymerase, thus blocking the cell apoptosis process mediated by endogenous or exogenous signals. As a result, hepatic failure is expected to be alleviated by F573. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Acute on Chronic Liver Failure (ACLF).

 Further product details are provided in the report……..

 

Acute On Chronic Liver Failure (ACLF): Therapeutic Assessment

This segment of the report provides insights about the different Acute On Chronic Liver Failure (ACLF) drugs segregated based on following parameters that define the scope of the report, such as:

• Major  Players in Acute On Chronic Liver Failure (ACLF)
• There are approx. 3+ key companies which are developing the therapies for Acute On Chronic Liver Failure (ACLF). The companies which have their Acute On Chronic Liver Failure (ACLF) drug candidates in the most advanced stage, i.e. Phase II include, Gyre Therapeutics.

 

Phases

DelveInsight’s report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

Acute On Chronic Liver Failure (ACLF) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

 

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

 

Acute On Chronic Liver Failure (ACLF): Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Acute On Chronic Liver Failure (ACLF) therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute On Chronic Liver Failure (ACLF) drugs.

 

Acute On Chronic Liver Failure (ACLF) Report Insights

• Acute On Chronic Liver Failure (ACLF) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

 

Acute On Chronic Liver Failure (ACLF) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Acute On Chronic Liver Failure (ACLF) drugs?
• How many Acute On Chronic Liver Failure (ACLF) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute On Chronic Liver Failure (ACLF)?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Acute On Chronic Liver Failure (ACLF) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Acute On Chronic Liver Failure (ACLF) and their status?
• What are the key designations that have been granted to the emerging drugs?